Atherogenic lipids and endothelial dysfunction: Mechanisms in the genesis of ischemic syndromes

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 149-167

  Adams, Mark R ^a   Kinlay, Scott ^a   Blake, Gavin J ^a   Orford, James L ^a   Ganz, Peter ^a   Selwyn, Andrew P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Cholesterol; Endothelium; Nitric oxide

Indexed keywords

NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; INFLAMMATION; ISCHEMIA; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

ARTERIOSCLEROSIS; CELL DIVISION; ENDOTHELIUM, VASCULAR; HUMANS; ISCHEMIA; LIPOPROTEIN(A); LIPOPROTEINS, LDL; NITRIC OXIDE; TRIGLYCERIDES; VASOMOTOR SYSTEM;

EID: 0034049508     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.149     Document Type: Review

References (112)

1. 1. PDAY Research Group. 1990. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA 264:3018-24
2. 2. Ross R. 1993. The pathogenesis of atherosclerosis; a perspective for the 1990s. Nature 362:801-9
3. 3. Castelli WP, Garrison RJ, Wilson PWF, et al. 1986. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 256:2835-38
4. 4. Mehta JL. 1995. Endothelium, coronary vasodilation, and organic nitrates. Am. Heart J. 129:382-91
5. 2) by layers of the arterial wall: an explanation for the anti-thrombotic properties of vascular endothelium. Thromb. Res. 11:323-44
6. 6. Hekman CM, Loskutoff DJ. 1987. Fibrinolytic pathways and the endothelium. Semin. Tliromb. Hemost. 13:514-27
7. 7. Joris I, Zand T, Nunnari JJ, Krolikowski FJ, Majno G. 1983. Studies on the pathogenesis of atherosclerosis. I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am. J. Pathol. 113:341-58
8. 8. Kinlay S, Selwyn AP, Delagrange D, et al. 1996. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr. Opin. Lipiol. 7:389-97
9. 9. Libby P. 1995. Molecular bases of the acute coronary syndromes. Circulation 92:2844-50
10. 10. Andrews HE, Bruckdorfer KR, Dunn RC, Jacobs M. 1987. Low-density lipo-proteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature 327: 237-39
11. 11. Freiman PC, Mitchell GG, Heistad DD, et al. 1986. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ. Res. 58:783-89
12. 12. Creager MA, Cooke JP, Mendelsohn ME, et al. 1990. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J. Clin. Invest. 86:228-34
13. 13. Dinerman JL, Mehta JL. 1990. Endothelial, platelet and leukocyte interactions in ischemic heart disease: insights into potential mechanisms and their clinical relevance. J. Am. Coll. Cardiol. 16:207-22
14. 14. Ganz P, Creager MA, Fang JC, et al. 1996. Pathogenetic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis. Am. J. Med. 101(4A):4A 10-16S
15. 15. Furchgott RF, Zawadzki JV. 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-76
16. 16. Meredith IT, Anderson TJ, Uehata A, et al. 1993. The role of the endothelium in ischemic coronary syndromes. Am. J. Cardiol. 72:27-32C
17. 17. Palmer RM, Ashton DS, Moncada S. 1988. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664-66
18. 18. Bassenge E, Keusch G. 1990. Endothelial and neuro-humoral control of coronary blood flow in health and disease. Rev. Physiol. Biochem. Pharmacol. 116:77-165
19. 19. Arnold WP, Mittal CK, Katsuki S, Murad F. 1977. Nitric oxide activates guanylate cyclase and increases guanosine 3:5'-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad. Sci. USA 74:3203-7
20. 20. Boulanger CM, Lüscher TF. 1990. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 85:587-90
21. 21. De Caterina R, Libby P, Peng H-B, et al. 1995. Nitric oxide decreases cytokine-induced endothelial activation. J. Clin. Invest. 96:60-68
22. 22. Cody RJ. 1992. The potential role of endothelin as a vasoconstrictor substance in congestive heart failure. Eur. Heart. J. 13:1573-78
23. 23. Cohen RA, Vanhoutte PM. 1995. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 92:3337-49
24. 24. Simari RD, San H, Rekhter M, et al. 1996. Regulation of cellular proliferation and intimai formation following balloon injury in atherosclerotic rabbit arteries. J. Clin. Invest. 98:225-35
25. 25. Rubanyi GM. 1993. The role of endothelium in cardiovascular homeostasis and diseases. J. Cardiovasc. Pharmacol. 22(Suppl. 4):S1-14
26. 26. Machovich R. 1986. Choices among the possible reaction routes catalyzed by thrombin. Ann. NY Acad. Sci. 485:170-83
27. 27. Stamler JS, Vaughan DE, Loscalzo J. 1989. Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin. Circ. Res. 65:796-804
28. 28. Cooke JP, Singer AH, Tsao P, et al. 1992. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 90:1168-72
29. 29. Jayakody L, Senaratne M, Thomson A, Kappagoda T. 1987. Endothelium-dependent relaxation in experimental atherosclerosis in the rabbit. Circ. Res. 60:251-64
30. 30. Ludmer PL, Selwyn AP, Shook TL, et al. 1986. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315:1046-51
31. 31. Nabel EG, Selwyn AP, Ganz P. 1990. Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J. Am. Coll. Cardiol. 16:349-56
32. 32. Zeiher AM, Drexler H, Wollschlager H, Just H. 1991. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 83:391-401
33. 33. Celermajer DS, Sorensen KE, Gooch VM, et al. 1992. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-15
34. 34. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. 1987. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J. Clin. Invest. 80:1808-11
35. 35. Chappell SP, Lewis MJ, Henderson AH. 1987. Effect of lipid feeding on endothelium-dependent relaxation in rabbit aortic preparations. Cardiovasc. Res. 21:34-38
36. 36. Zeiher AM, Drexler H, Saurbier B, Just H. 1993. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia and hypertension. J. Clin. Invest. 92:652-62
37. 37. Adams MR, Robinson J, McCredie R, et al. 1998. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J. Am. Coll. Cardiol. 32:123-27
38. 38. Gordon JB, Ganz P, Nabel EG, et al. 1989. Atherosclerosis and endothelial function influence the coronary vasomotor response to exercise. J. Clin. Invest. 83:1946-52
39. 39. Goldstein JL, Kita T, Brown MS. 1983. Defective lipoprotein receptors and atherosclerosis: lessons from an animal counterpart of familial hypercholesterolemia. M Engl. J. Med. 309:288-96
40. 40. Fuster V, Badimon L, Badimon JJ, Chesebro JH. 1992. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 326:310-18
41. 41. Amman V, Nilsson A, Stemme S, et al. 1994. Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins. Thromb. Res. 76:487-99
42. 42. Hamsten A. 1991. Hemostatic function and coronary disease. N. Engl. J. Med. 332:677-78
43. 43. Szczeklik A, Musial J, Undas A, et al. 1996. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 16:948-54
44. 44. Davi G, Ganci A, Averna M, et al. 1995. Thromboxane biosynthesis, neutrophil and coagulation activation in type IIa hypercholesterolemia. Thromb. Haemost. 74:1015-19
45. 45. Sellke FW, Armstrong ML, Harrison DG. 1990. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 81:1586-93
46. 46. Cohen RA, Zitnay KM, Haudenschild CC, Cunningham LD. 1988. Loss of selective endothelial cell vasoactive functions caused by hypercholesterolemia in pig coronary arteries. Circ. Res. 63:903-10
47. 47. Steinberg D. 1991. Antioxidants and atherosclerosis. A current assessment. Circulation 84:1420-25
48. 48. Kugiyama K, Kerns SA, Morrisett JD, et al. 1990. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344:116-62
49. 49. Steinbrecher UP. 1987. Oxidation of human low-density lipoprotein results in esterification of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262: 3603-8
50. 50. Freigang S, Horkko S, Miller E, et al. 1998. Immunization of LDL receptor-deficient mice with homologous malondialehyde - modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18:1972-82
51. 51. Cox DA, Cohen ML. 1996. Effects of low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Pharmacol. Rev. 48:3-19
52. 52. Simon BC, Cunningham LD, Cohen RA. 1990. Low-density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J. Clin. Invest. 86:75-79
53. 53. Anderson TJ, Meredith IT, Charbonneau F, et al. 1996. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 93:1647-50
54. 54. Raitakari OT, Pitkänen OP, Lehtimäki T, et al. 1997. In vivo low-density lipoprotein oxidation relates to coronary reactivity in young men. J. Am. Coll. Cardiol. 30:97-102
55. 55. Pritchard KA, Groszek L, Smalley DM, et al. 1995. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ. Res. 77:510-18
56. 56. Ohara Y, Peterson TE, Harrison DG. 1993. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91:2546-51
57. 57. Gryglewski RJ, Palmer RM, Moncada S. 1986. Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature 320:454-56
58. 58. Garcia CE, Kilcoyne CM, Cardillo C, et al. 1995. Evidence that endothelial dysfunction in patients with hypercholesterolemia is not due to increased extracellular nitric oxide breakdown by superoxide onions. Am. J. Cardiol. 76: 1157-61
59. 59. Liao JK, Shin WS, Lee WY, Clark SL. 1995. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J. Biol. Chem. 270:319-24
60. 60. Ohara Y, Sayegh HS, Yamin JJ, Harrison DG. 1995. Regulation of endothelial constitutive nitric oxide synthase by protein kinase C. Hypertension 25:415-20
61. ia subunit expression by oxidized low-density lipoprotein. J. Clin. Invest. 95:1457-63
62. 62. Bode-Böger SM, Böger RH, Kienke S, et al. 1996. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem. Biophys. Res. Commun. 219: 598-603
63. 63. Vallance P, Leone A, Calver A, et al. 1992. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-75
64. 64. Chen LY, Mehta P, Mehta JL. 1996. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Circulation 93:1740-46
65. 65. Hodgson JM, Marshall JJ. 1989. Direct vasoconstriction and endothelium-dependent vasodilation. Mechanisms of acetylcholine effects on coronary flow and arterial diameter in patients with nonstenotic coronary arteries. Circulation 79:1043-51
66. 66. Vita JA, Treasure CB, Nabel EG, et al. 1990. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81:491-97
67. 67. Drexler H, Zeiher AM, Wollschlager H, et al. 1989. Flow-dependent coronary artery dilatation in humans. Circulation 80:466-74
68. 68. Gilligan DM, Guetta V, Panza JA, et al. 1994. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 90:35-41
69. 69. Celermajer DS, Sorensen KE, Bull C, et al. 1994. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J. Am. Coll. Cardiol. 24:1468-74
70. 70. Faggiotto A, Ross R, Harker L. 1984. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 4:323-40
71. 71. Lefer AM, Ma XI. 1993. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler. Thromb. 13:771-76
72. 72. Mata P, Alonso R, Lopez-Farre A, et al. 1996. Effect of dietary fat saturation on LDL oxidation and monocyte adhesion to human endothelial cells in vitro. Arterioscler. Thromb. Vasc. Biol. 16:1347-55
73. 73. Cybulsky MI, Gimbrone MA. 1991. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251:788-91
74. 74. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. 1995. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J. Clin. Invest. 95:1262-70
75. 75. Kume N, Cybulsky MI, Gimbrone MA. 1992. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90:1138-44
76. 76. Xu XP, Meisel SR, Ong JM, et al. 1999. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 99: 993-98
77. 77. Dimmeler S, Haendeler J, Galle J, Zeiher AM. 1997. Oxidised low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. Circulation 95:1760-63
78. 78. Radomski MW, Palmer RM, Moncada S. 1987. Comparative pharmacology of endothelial-derived relaxing factor and prostacyclin in platelets. J. Pharmacol. 92:181-87
79. 79. Boulanger CM, Tanner FC, Béa ML, et al. 1992. Oxidied low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ. Res. 70: 1191-97
80. 80. Sorensen KE, Celermajer DS, Georgakopoulos D, et al. 1994. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J. Clin. Invest. 93:50-55
81. 81. Schächinger V, Halle M, Minners J, et al. 1997. Lipoprotein (a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J. Am. Coll. Cardiol. 30:927-34
82. 82. Galle J, Bengen J, Schollmeyer P, Wanner C. 1995. Impairment of endothelium-dependent dilation in rabbit arteries by oxidized lipoprotein (a): role of oxygen derived radicals. Circulation 92:1582-89
83. 83. Allen S, Khan S, Tam SP, et al. 1998. Expression of adhesion molecules by 1p(a): a potential novel mechanism for its atherogenicity. FASEB J. 12:1765-76
84. 84. Steinberg HO, Chaker H, Leaming R, et al. 1996. Obesity/insulin resistance is associated with endothelial dysfunction. J. Clin. Invest. 97:2601-10
85. 85. Clarkson P, Celermajer DS, Donald AE, et al. 1996. Impaired vascular reactivity in insulin dependent diabetes mellitus is related to disease duration and LDL-cholesterol levels. J. Am. Coll. Cardiol. 28:573-79
86. 86. McVeigh GE, Brennan GM, Johnston GD, et al. 1992. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:771-76
87. 87. Chowienczyk PJ, Watts GF, Wierzbicki AS, et al. 1997. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity. J. Am. Coll. Cardiol. 29:964-68
88. 88. Sattar N, Petrie JR, Jaap AJ. 1998. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 138:229-35
89. 89. Takahashi M, Yui Y, Yasumoto H, et al. 1990. Lipoproteins are inhibitors of endothelium-dependent relaxation of rabbit aorta. Am. J. Physiol. 258:H1-8
90. 90. Vedernikov YP, Lankin VZ, Tikhaze AC, Vikhert AM. 1988. Lipoproteins as factors in vessel tone and reactivity modulation. Basic Res. Cardiol. 83:590-96
91. 91. Cockerill GW, Rye KA, Gamble JR, et al. 1995. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15: 1987-94
92. 92. Zeiher AM. 1996. Endothelial vasodilator dysfunction: pathogenetic link to myocardial ischaemia or epiphenomenon? Lancet 348(Suppl. 1):s10-12
93. 93. Keaney JF, Xu A, Cunningham D, et al. 1995. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J. Clin. Invest. 96:2520-29
94. 94. Leung WH, Lau CP, Wong CK. 1993. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 341:1496-500
95. 95. Treasure CB, Klein JL, Weintraub WS, et al. 1995. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332:481-87
96. 96. Anderson TJ, Meredith IT, Yeung AC, et al. 1995. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332: 488-93
97. 97. Egashira K, Hirooka Y, Kai H, et al. 1994. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89:2519-24
98. 98. Simons LA, Sullivan D, Simons J, Celermajer DS. 1998. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis 137:197-203
99. 99. O'Driscoll G, Green D, Taylor RR. 1997. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within one month. Circulation 95:1126-31
100. 100. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. 1995. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 346:467-71
101. 101. Tamai O, Matsuoka H, Itabe H, et al. 1997. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95:76-82
102. 102. Reilly MP, Pratico D, Delanty N, et al. 1998. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 98:2822-28
103. 103. Lacoste L, Lam JY, Hung J, et al. 1995. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 92:3172-77
104. 104. Blankenhorn DH, Hodis HN. 1994. George Lyman Duff memorial lecture. Arterial imaging and atherosclerosis reversal. Arterioscler. Thromb. 14:177-92
105. 105. Libby P, Aikawa M. 1998. New insights into plaque stabilisation by lipid lowering. Drugs 56(Suppl. 1):9-13
106. 106. Hackman A, Abe Y, Insull W, et al. 1996. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 93:1334-38
107. 107. Shepherd J, Cobbe SM, Ford I, et al. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333:1301-7
108. 108. Scandinavian Simvastatin Survival Group. 1994. Randomised trial of cholesterol lowering therapy in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-89
109. 109. Andrews TC, Raby K, Barry J, et al. 1997. The effect of LDL cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 95:324-28
110. 110. Brown BG, Maher VM. 1994. Reversal of coronary heart disease by lipid-lowering therapy. Observations and pathological mechanisms. Circulation 89:2928-33
111. 111. Lehr HA, Frei B, Arfors KE. 1994. Vitamin C prevents cigarette smoke-induced leukocyte aggregation and adhesion to endothelium in vivo. Proc. Natl. Acad. Sci. USA 91:7688-92
112. 112. Clarkson P, Adams MR, Powe AJ, et al. 1996. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J. Clin. Invest. 97:1989-94